BioCryst Pharma price target lowered to $25 by Citizens on HAE outlook
NegativeFinancial Markets

BioCryst Pharma price target lowered to $25 by Citizens on HAE outlook
Citizens has lowered its price target for BioCryst Pharma to $25, reflecting concerns about the company's outlook on hereditary angioedema (HAE). This adjustment is significant as it indicates potential challenges for BioCryst in meeting market expectations, which could impact investor confidence and the company's future growth prospects.
— via World Pulse Now AI Editorial System


